10 May 2022>: Original Paper
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional StudyBruno Roche 1BCDE , Artur Bauhofer 2ACDEF* , Miguel Ãngel Gomez Bravo 3BCDE , Georges Philippe Pageaux 4ABCDE , Fabien Zoulim 5BDE , Alejandra Otero 6BC , Martin Prieto 78BC , Carmen Baliellas 9BC , Didier Samuel 1ACDE
Ann Transplant 2022; 27:e936162
Figure 2 Proportion of patients with serum anti-HBs trough levels at/above or below 100 IU/L under treatment with s.c. HBIg. Percentages are based on patients with quantitative anti-HBs test results available at the respective visits (number in brackets). FU last: last available anti-HBs value documented in a patient (Prepared with Microsoft Office 2016).ADR – adverse drug reaction (adverse event possibly related to treatment with sc HBIg); MedDRA – Medical Dictionary for Regulatory Activities; PT – preferred term.